Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RxSight (RXST) Total Current Liabilities (2020 - 2026)

RxSight filings provide 6 years of Total Current Liabilities readings, the most recent being $26.3 million for Q4 2025.

  • On a quarterly basis, Total Current Liabilities rose 1.46% to $26.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $26.3 million, a 1.46% increase, with the full-year FY2025 number at $26.3 million, up 1.46% from a year prior.
  • Total Current Liabilities hit $26.3 million in Q4 2025 for RxSight, up from $22.3 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $26.3 million in Q4 2025 to a low of $9.2 million in Q3 2021.
  • Median Total Current Liabilities over the past 5 years was $18.3 million (2024), compared with a mean of $17.8 million.
  • Biggest five-year swings in Total Current Liabilities: fell 4.51% in 2021 and later skyrocketed 78.38% in 2022.
  • RxSight's Total Current Liabilities stood at $11.1 million in 2021, then surged by 55.61% to $17.2 million in 2022, then increased by 21.27% to $20.9 million in 2023, then grew by 23.79% to $25.9 million in 2024, then increased by 1.46% to $26.3 million in 2025.
  • The last three reported values for Total Current Liabilities were $26.3 million (Q4 2025), $22.3 million (Q3 2025), and $20.4 million (Q2 2025) per Business Quant data.